Trial in Patients With Relapsed Ovarian Cancer
NCT03267589
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators
[object Object]
[object Object]